Blood Markers in Acute Myeloid Leukemia After Stem Cell Transplant Treated With Menin Inhibitors
Studies white blood cells of adults whose leukemia returned after a stem cell transplant.
Plain-language title generated from the registry record
Registry title: Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition.
Key facts
- Where
- Freiburg im Breisgau, GermanySee the site
Where in Germany
- University of Freiburg Mdical CenterFreiburg im Breisgau, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Freiburg
- Trial code
- NCT07627568
- Record updated
- 10 June 2026
- Original description
The white blood cells of patients with acute myeloid leukemia that have undergone allogeneic stem cell transplantation will be investigated. These are patient where the leukemia has returned after the transplantation.Read full original descriptionShow less
Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition.
The white blood cells of patients with acute myeloid leukemia that have undergone allogeneic stem cell transplantation will be investigated. These are patient where the leukemia has returned after the transplantation.
Inclusion: Diagnosis of acute myeloid leukemia with NPM1 mutations or KMT2A rearrangements; Hematological relapse after allo-HCT; 18 years or older.
Exclusion: no signed informed consent.